Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Benitec Biopharma (BNTC) Return on Capital Employed (2020 - 2025)

Benitec Biopharma's Return on Capital Employed history spans 4 years, with the latest figure at 1.18% for Q4 2023.

  • For Q4 2023, Return on Capital Employed changed N/A year-over-year to 1.18%; the TTM value through Dec 2023 reached 1.18%, changed N/A, while the annual FY2024 figure was 0.96%, 1442.0% up from the prior year.
  • Return on Capital Employed for Q4 2023 was 1.18% at Benitec Biopharma, up from 1.82% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.85% in Q2 2021 and bottomed at 1.95% in Q3 2022.
  • The 4-year median for Return on Capital Employed is 1.06% (2020), against an average of 1.27%.
  • The largest YoY upside for Return on Capital Employed was 13bps in 2023 against a maximum downside of 13bps in 2023.
  • A 4-year view of Return on Capital Employed shows it stood at 0.96% in 2020, then grew by 11bps to 0.85% in 2021, then plummeted by -130bps to 1.95% in 2022, then surged by 40bps to 1.18% in 2023.
  • Per Business Quant, the three most recent readings for BNTC's Return on Capital Employed are 1.18% (Q4 2023), 1.82% (Q3 2023), and 1.95% (Q3 2022).